[{"id":"447ed126-6f5f-4987-b043-27e335f9b442","acronym":"C1763102","url":"https://clinicaltrials.gov/study/NCT05602363","created_at":"2024-01-29T15:19:20.293Z","updated_at":"2025-02-25T14:09:14.782Z","phase":"Phase 1","brief_title":"AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05602363 - C1763102","lead_sponsor":"Carna Biosciences, Inc.","biomarkers":" PLCG2","pipe":" | ","alterations":" PLCG2 mutation","tags":["PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docirbrutinib (AS-1763)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-11-01"}]